News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vertex Pharmaceuticals (MA) (VRTX) Goes From Bad Data to a Bad Promotion


5/31/2012 6:58:45 AM

This is not a good week for the executive team at Vertex Pharmaceuticals. Two days ago, the drugmaker revised previously announced interim results of a Phase II study of a combination cystic fibrosis treatment, taking the wind out of its once hot stock and tarnishing its credibility (see here). Now, the FDA has issued a so-called untitled letter for a promotional push for its Incivek hepatitis C treatment for including misleading material.

Read at Pharmalot

comments powered by Disqus
Pharmalot
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES